Abstract
Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors.
Keywords: PARP inhibitor, DNA repair, pharmacogenetics, drug response, cancer, veliparib, talazoparib.
Current Pharmacogenomics and Personalized Medicine
Title:Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors
Volume: 16 Issue: 2
Author(s): Wei-Hua Shao, Lei-Yun Wang and Ji-Ye Yin*
Affiliation:
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008,China
Keywords: PARP inhibitor, DNA repair, pharmacogenetics, drug response, cancer, veliparib, talazoparib.
Abstract: Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors.
Export Options
About this article
Cite this article as:
Shao Wei-Hua , Wang Lei-Yun and Yin Ji-Ye *, Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors, Current Pharmacogenomics and Personalized Medicine 2018; 16 (2) . https://dx.doi.org/10.2174/1875692116666180821152601
DOI https://dx.doi.org/10.2174/1875692116666180821152601 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry Q-TOF LC/MS-based Untargeted Metabolomics Approach to Evaluate the Effect of Folate-Conjugated Cyclodextrins on Triple-Negative Breast Cancer Cells
Current Pharmaceutical Analysis Overview of Base Excision Repair Biochemistry
Current Molecular Pharmacology The Impact of Comorbid Diabetes Type 2 on Quality of Life in Cancer Patients Undergoing Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Breast Cancer: A Review of Risk Factors and New Insights into Treatment
Current Cancer Therapy Reviews RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry A Meta-Analysis of Proteomic Blood Markers of Colorectal Cancer
Current Medicinal Chemistry Exosome as a Natural Gene Delivery Vector for Cancer Treatment
Current Cancer Drug Targets Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer
Current Gene Therapy High Throughput Study for Molecular Mechanism of Metformin Pre-Diabetic Protection <i>via</i> Microarray Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets MicroRNAs and Pancreatic Cancer: Current Research and Future Outlooks
Current Signal Transduction Therapy Graphene and Graphene Oxide as a Docking Station for Modern Drug Delivery System
Current Drug Delivery Ultrasound Therapeutics– A Review
Current Medical Imaging Effects of Iron Chelation in Osteosarcoma
Current Cancer Drug Targets Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
Current Topics in Medicinal Chemistry Novel and Emerging Drugs for Rarer Chronic Lymphoid Leukaemias
Current Cancer Drug Targets Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry